HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Graber, S. E. Articles by Hawiger, J. Search for Related Content PubMed PubMed Citation Articles by Graber, S. E. Articles by Hawiger, J. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 257, Issue 24, 14606-14609, 12, 1982

Evidence that changes in platelet cyclic AMP levels regulate the fibrinogen receptor on human platelets

SE Graber and J Hawiger

Fibrinogen binds to human platelets after specific receptor sites are exposed by thrombin, ADP, epinephrine, and other stimuli. Since prostaglandin I2 (PGI2), a potent activator of platelet adenylate cyclase, prevents mobilization of the fibrinogen receptor by aggregating agents, we investigated the relationship between platelet cAMP levels and fibrinogen receptor status in thrombin-stimulated human platelets. A dose-dependent rise in platelet cAMP in response to two adenylate cyclase agonists, PGI2 and forskolin, correlated with progressive inhibition of fibrinogen binding. Moreover, the receptor inhibition produced by either agonist was sustained up to 2 h and was associated with a persistent increase in cAMP levels. The phosphodiesterase inhibitor, 1-methyl-3-isobutylxanthine, in the presence of a subthreshold concentration of PGI2 also raised cAMP and inhibited fibrinogen binding. In contrast, the effects of PGI2 on both cAMP and fibrinogen binding were markedly attenuated by 9-(tetrahydro-2- furyl) adenine, an adenylate cyclase inhibitor. These results indicate that the inhibition of fibrinogen binding by PgI2 is linked to its effect on cAMP levels and suggest that elevation of platelet cAMP levels from any cause prevents exposure of the fibrinogen receptor.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				T. Hato, N. Pampori, and S. J. Shattil Complementary Roles for Receptor Clustering and Conformational Change in the Adhesive and Signaling Functions of Integrin alpha IIbbeta 3 J. Cell Biol., June 29, 1998; 141(7): 1685 - 1695. [Abstract] [Full Text] [PDF]

				H. Kashiwagi, M. A. Schwartz, M. Eigenthaler, K.A. Davis, M. H. Ginsberg, and S. J. Shattil Affinity Modulation of Platelet Integrin alpha IIbbeta 3 by beta 3-Endonexin, a Selective Binding Partner of the beta 3 Integrin Cytoplasmic Tail J. Cell Biol., June 16, 1997; 137(6): 1433 - 1443. [Abstract] [Full Text] [PDF]

				M. Si-Tahar, D. Pidard, V. Balloy, M. Moniatte, N. Kieffer, A. Van Dorsselaer, and M. Chignard Human Neutrophil Elastase Proteolytically Activates the Platelet Integrin alpha IIbbeta 3 through Cleavage of the Carboxyl Terminus of the alpha IIb Subunit Heavy Chain. INVOLVEMENT IN THE POTENTIATION OF PLATELET AGGREGATION J. Biol. Chem., April 25, 1997; 272(17): 11636 - 11647. [Abstract] [Full Text] [PDF]